Thalassemia Foundation of America
Formerly Cooley's Anemia Foundation

2027-2028 ONGOING CLINICAL RESEARCH IN THALASSEMIA

The Thalassemia Foundation of America (Formerly Cooley's Anemia Foundation) invites national and international applicants to apply for grants to support Ongoing Clinical Research projects in thalassemia.

The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the following areas impacting patients with thalassemia, including but not limited to: cardiac issues and iron overload; fertility, pregnancy and family planning; bone health, quality of life, psychosocial impact and/or burden of disease.

The stipends will be $50,000 annually with the possibility of one-year renewal upon submission of a renewal application. Approval will be based upon scientific merit, feasibility, and availability of funds. Funds may be used for either salary or non-salary purposes, but the administrative cost is limited to 10% of the total amount granted.

This level of funding would be appropriate for support of innovative small-scale pilot studies, observational trials, or ancillary support for ongoing interventional studies (for example, support of a trainee joining an existing trial, or new biological endpoint analyses for an existing trial). In the case of ancillary studies, investigators should clearly document the support for the parent trial in their "other support" declarations.

Junior and senior faculty are eligible; fellows and trainees are not eligible. Investigators must interact directly with patients or patient-related data**.** Basic research, when included in this "Ongoing Clinical Research" program, must be related to a **direct clinical focus of the grant application**.

Assurance must be given that adequate facilities exist and will continue to be available to conduct the research project and that the project has been reviewed and approved by the appropriate committee or governing body on human research. The research may not be conducted at a for-profit laboratory.

All publications resulting from the Thalassemia Foundation of America sponsored grants should bear the statement: This study was supported by a grant from the Thalassemia Foundation of America.

LETTER OF INTENT

Interested individuals are invited to submit a letter of intent by **Monday, December 21, 2026**, which includes the name of primary applicant, affiliation, and focus of proposal (not to exceed one paragraph). The completed application (including letters of reference, which must be submitted by the authors of the letters) is due **Monday, February 1, 2027**. Both the letter of intent and the application should be emailed in PDF format to **grants@thalassemia.org**. All applicants will be notified in **May 2027** regarding the status of their funding.

GUIDELINES FOR COMPLETING THE APPLICATION

Please use Arial or Calibri, font size 11 for the application.

COVER PAGE

Please complete and attach the form provided on page 4.

NON-TECHNICAL ABSTRACT *(Not to exceed 250 words)*

Please provide an abstract using language easily understandable by a non-technical reader.

PROPOSAL

Please use Arial or Calibri font, size 11.

The proposal should include the following sections:

I. ABSTRACT *(up to 30 lines, excluding title)*
Technical abstract

II. SPECIFIC AIMS *(up to 1 page)*
Including a brief overview of the experimental design

III. BACKGROUND, SIGNIFICANCE AND INNOVATION *(1 page)*
Include an overview of the importance of the proposed research to the field and to TFA's mission. Provide a rationale for the proposal and lay the groundwork for the study.

IV. PRELIMINARY STUDIES *(1 page, including figures)*

V. RESEARCH DESIGN AND METHODS *(Up to 4 pages), including (for each Aim)*

- Description of methods and analyses to be used to accomplish the specific aims of the project
- Expected results, including discussion of the way in which the results will be collected, analyzed, and interpreted
- Sample size calculation and statistical analysis plan
- Discussion of potential difficulties and limitations and how these will be overcome or mitigated
- If the project is in the early stages of development, describe any strategy to establish feasibility, and address management of any high-risk aspects of the proposed work
- Page count includes figures and tables
- A projected timetable should be included (work plan)

VI. REFERENCES
Not included in page count

VII. FACILITIES AVAILABLE *(Up to 1 page)*

VIII. OTHER SUPPORT OF THE APPLICATION & SPONSOR

Please list title, amount per year and duration of all research support including pending applications, whether related to this proposal or not. When this grant is proposed to be used for ancillary studies to an ongoing clinical trial, the financial support of the trial must be cited here.

IX. HUMAN SUBJECTS

If human subjects are involved, explain the risk, risk-benefit ratio, and methods of obtaining informed consent and of preserving confidentiality; submit evidence of approval of the project by the committee for the protection of human subjects (Institutional Review Board) of the sponsoring institution. For drug studies, include documentation of FDA approval for use of an investigational new drug (IND) if applicable.

X. BIOGRAPHICAL SKETCH AND CAREER PLAN

Submit an NIH biographical sketch using SciENcv. Submit a paragraph describing your short-term and long-term career goals.

XI. PROFESSIONAL REFERENCES *(Junior faculty applicants only)*

Junior faculty applicants must submit the names of two individuals under whose supervision you have worked or trained most recently. Ask each of them to comment on your knowledge, training and research ability by sending letters in PDF format to **grants@thalassemia.org**.

Applications from junior faculty applicants will not be considered unless all letters of reference have been received. It is the responsibility of the applicant to ensure that the letters of recommendation have been sent by **Monday, February 1, 2027** deadline. Letters of recommendation submitted with the application will not be considered.

XII. BUDGET FOR PERIOD JULY 1, 2027 TO JUNE 30, 2028

Support is available for salary, fringe benefits, study-related costs, and a maximum 10% for administrative costs.

A. Salary
B. Fringe Benefits
C. Non-Salary expenses
D. Total (not to exceed $50,000)
Please indicate total salary and all other sources of support, if any

XIII. AGREEMENTS

Please attach completed page 5.

2027-2028 ONGOING CLINICAL RESEARCH IN THALASSEMIA

COVER PAGE

Applicant Information

Research Proposal Title

Applicant Name	**Applicant Title**

Mailing Address

Telephone	**Email**

Disbursement Information

Institution Contact Name	**Department**

Check Payable to	**Institution's Federal Identification Number**

Mailing Address

AGREEMENT

I agree with the policies of the Thalassemia Foundation of America (Formerly Cooley's Anemia Foundation) concerning this application. I certify that I have appropriate facilities to complete the proposed research. Subsequent publications will acknowledge funding by the Thalassemia Foundation of America.

Applicant Name	**Signature**

Additional Signatures

Chairman or Director Name	**Department**

Signature

Administrative Officer Name	**Telephone**

Signature

Financial Officer Name	**Telephone**

Signature

Approved Human Research Committee

Chairman Name	**Date**

Signature
